In conclusion, the emerging paradigm of molecularly targeted therapies, particularly the combination of Dabrafenib and Trametinib, has revolutionized the treatment landscape for pediatric gliomas with BRAF mutations. This evidence concerns the gene BRAF and central nervous system cancer.